Tex. Occ. Code Section 562.001
Definitions


In this subchapter:

(1)

“Biological product” has the meaning assigned by Section 351, Public Health Service Act (42 U.S.C. Section 262).

(1-a)

“Generically equivalent” means a drug that is pharmaceutically equivalent and therapeutically equivalent to the drug prescribed.

(1-b)

“Interchangeable,” in reference to a biological product, has the meaning assigned by Section 351, Public Health Service Act (42 U.S.C. Section 262), or means a biological product that is designated as therapeutically equivalent to another product by the United States Food and Drug Administration in the most recent edition or supplement of the United States Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.

(2)

“Pharmaceutically equivalent” means drug products that have identical amounts of the same active chemical ingredients in the same dosage form and that meet the identical compendial or other applicable standards of strength, quality, and purity according to the United States Pharmacopoeia or another nationally recognized compendium.

(3)

“Therapeutically equivalent” means pharmaceutically equivalent drug products that, if administered in the same amounts, will provide the same therapeutic effect, identical in duration and intensity.
Acts 1999, 76th Leg., ch. 388, Sec. 1, eff. Sept. 1, 1999.
Amended by:
Acts 2015, 84th Leg., R.S., Ch. 1007 (H.B. 751), Sec. 1, eff. September 1, 2015.

Source: Section 562.001 — Definitions, https://statutes.­capitol.­texas.­gov/Docs/OC/htm/OC.­562.­htm#562.­001 (accessed Mar. 23, 2024).

562.001
Definitions
562.002
Legislative Intent
562.003
Disclosure of Price
562.004
Prescription Transmitted Orally by Practitioner
562.005
Record of Dispensed Drug or Biological Product
562.006
Label
562.007
Refills
562.008
Generic Equivalent or Interchangeable Biological Product Authorized
562.009
Requirements Concerning Selection of Generically Equivalent Drug or Interchangeable Biological Product
562.010
Responsibility Concerning Generically Equivalent Drug or Interchangeable Biological Product
562.011
Restriction on Selection of and Charging for Generically Equivalent Drug or Interchangeable Biological Product
562.012
Substitution of Dosage Form Permitted
562.013
Applicability of Subchapter
562.014
Narrow Therapeutic Index Drugs
562.015
Dispensing Directive
562.016
List of Approved Interchangeable Biological Products
562.0051
Communication Regarding Certain Dispensed Biological Products
562.052
Release of Confidential Records
562.053
Reports to Board
562.054
Emergency Refills
562.055
Report to Texas Department of Health
562.056
Practitioner-patient Relationship Required
562.057
Administration of Epinephrine
562.0061
Other Prescription Information
562.0062
Required Statement Regarding Medication Disposal
562.101
Supervision of Pharmacy
562.102
Confidential Record
562.103
Display of Licenses by Pharmacy
562.104
Toll-free Telephone Number Required
562.105
Maintenance of Records
562.106
Notification
562.107
Written Consumer Information Required
562.108
Emergency Medication Kits
562.109
Automated Pharmacy Systems
562.110
Telepharmacy Systems
562.112
Practitioner-patient Relationship Required
562.0141
Transplant Immunosuppressant Drug Product Selection Prohibited
562.0142
Adoption of Rules
562.151
Definitions
562.152
Compounding for Office Use
562.153
Requirements for Office Use Compounding
562.154
Distribution of Compounded and Prepackaged Products to Certain Pharmacies
562.155
Compounding Service and Compounded Drug Products
562.156
Compounded Sterile Preparation
562.0541
Emergency Refills of Insulin and Insulin-related Equipment or Supplies
562.1011
Operation of Class C Pharmacy in Certain Rural Hospitals
562.1045
Linking Internet Sites
562.1085
Unused Drugs Returned by Certain Pharmacists
562.1086
Limitation on Liability

Accessed:
Mar. 23, 2024

§ 562.001’s source at texas​.gov